Ravandi, F., Ritchie, E., Sayar, H., Lancet, J., Craig, M. D., Vey, N., … Stuart, R. K. (2014). Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR). In BLOOD (Vol. 124). San Francisco, CA: AMER SOC HEMATOLOGY.

Ravandi, Farhad, Ellen Ritchie, Hamid Sayar, Jeffrey Lancet, Michael D. Craig, Norbert Vey, Stephen A. Strickland, et al. “Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR).” In BLOOD, Vol. 124. AMER SOC HEMATOLOGY, 2014.

Ravandi F, Ritchie E, Sayar H, Lancet J, Craig MD, Vey N, et al. Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR). In: BLOOD. AMER SOC HEMATOLOGY; 2014.

Ravandi, Farhad, et al. “Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR).” BLOOD, vol. 124, no. 21, AMER SOC HEMATOLOGY, 2014.

Ravandi F, Ritchie E, Sayar H, Lancet J, Craig MD, Vey N, Strickland SA, Schiller G, Jabbour E, Erba HP, Pigneux A, Horst H-A, Recher C, Klimek VM, Cortes J, Feldman EJ, Craig AR, Fox JA, Ward R, Smith J, Acton G, Mehta C, Kantarjian HM, Stuart RK. Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR). BLOOD. AMER SOC HEMATOLOGY; 2014.